Our goal: to enable the analysis of any living thing, by any person, in any environment
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs or in the field, and in real time. We continually improve the technology performance, make it easier to use and expand the ways in which users can access nanopore sequencing. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment.
Oxford Nanopore has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real-time, long-read, low-cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real-world applications such as disease/pathogen surveillance, environmental monitoring, food-chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in more than 70 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field.
Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The high-throughput, high-sample number PromethION is currently being prepared for release in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA-based analyses easy enough for any user and so we are working to simplify the sample preparation and data-analysis processes. For sample preparation, this includes a 5–10 minute sample prep kit and VolTRAX , a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
Metrichor Ltd is a company formed by Oxford Nanopore. It offers end-to-end analysis solutions coupled with nanopore sensing devices, with the goal of making analyses accessible to people without bioinformatics skills or even biology qualifications. This may include 'applied markets' such as food/environmental testing, or future consumer genetics applications.
Nanopore devices can be adapted for direct sequencing of DNA or RNA. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.
Oxford Nanopore Technologies Ltd is a private company headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices in Cambridge (UK), New York and Boston, and personnel also based in Japan and France.
The Company was founded in 2005 to develop a disruptive, electronic, single-molecule sensing system based on nanopore science. The first product, MinION, was introduced into early access in 2014 and made commercially available in 2015. The scaled-up GridION and PromethION appear in 2017. The Company has a rich development pipeline that includes the mobile-phone-compatible SmidgION.
The Company now has more than 300 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Oxford Nanopore was founded on the science of Professor Hagan Bayley of the University of Oxford. In 2008 the Company created a series of collaborations with world-leading nanopore researchers at other institutions including Harvard, University of California Santa Cruz and Boston University. Further collaborations have since been added; these, in combination with in-house expertise and Intellectual Property give the company a leading position in nanopore technology.
The Company has raised £351m to date in the following fundraising rounds, and is currently well funded for the next phase of corporate development. The Company does not have traditional Venture Capital investment; instead, the investor profile more closely mirrors those of publicly listed companies.
Seed funding was obtained in two rounds, from IP Group in 2005. In June 2006 the company raised £7.75m, and in March 2008 the company raised a further £10m. In January 2009 the Company announced an $18m (£11.9m) investment from Illumina and a separate commercialisation agreement with Illumina for the Company's exonuclease sequencing technology. In this round the Company also raised an additional £2.1m in private investment from other sources. In February 2010 Oxford Nanopore raised £17.4m from existing investors and new, undisclosed US-based investors.
In April 2011 the Company raised £25m from existing and new institutional and independent investors based in
the UK and US.
In May 2012 the Company raised £31.4m ($50.8m), the majority of which was from existing investors.
In October 2013 Oxford Nanopore raised £40m from new and existing investors in the US and Europe.
In November 2013 Oxford Nanopore performed a secondary placing and divested Illumina's stake in the
In August 2014 Oxford Nanopore raised £35m from new and existing investors in the US and Europe.
In July 2015 Oxford Nanopore raised £70m from new and existing investors in the US and Europe.
In December 2016 Oxford Nanopore raised £100m from new and existing investors worldwide.
At this stage, Oxford Nanopore is not seeking additional investment. However, if you are interested in receiving
information at the next opportunity then please use our contact form.